The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
复制标题
DOI：
10.1038/nrclinonc.2016.65
复制
发表时间：
2016-06
期刊：
影响因子：
--
通讯作者：
Wolchok JD
中科院分区：
文献类型：
--
作者：
Khalil DN;Smith EL;Brentjens RJ;Wolchok JD
在过去的十年中，单克隆抗体（mab）和过继细胞疗法通过调节免疫反应来治疗癌症的进展，使晚期肿瘤患者获得了前所未有的应答，否则这些患者将是致命的。迄今为止，三种免疫检查点阻断单抗已在美国被批准用于治疗几种类型的癌症患者，在未来的几个月和几年里，更多的患者将从免疫调节单抗治疗中受益。同时，基因修饰淋巴细胞的过继性转移治疗血液系统恶性肿瘤患者已经取得了显著的效果，我们预计这种方法将迅速成为越来越多患者的标准治疗方法。在这篇综述中，我们强调了免疫治疗的最新进展，并讨论了它在未来癌症治疗中的作用，包括推荐的联合策略和“装甲”CAR - T细胞的测试环境。
In the past decade, advances in the use of monoclonal antibodies (mAbs) and adoptive cellular therapy to treat cancer by modulating the immune response have led to unprecedented responses in patients with advanced-stage tumours that would otherwise have been fatal. To date, three immune-checkpoint-blocking mAbs have been approved in the USA for the treatment of patients with several types of cancer, and more patients will benefit from immunomodulatory mAb therapy in the months and years ahead. Concurrently, the adoptive transfer of genetically modified lymphocytes to treat patients with haematological malignancies has yielded dramatic results, and we anticipate that this approach will rapidly become the standard of care for an increasing number of patients. In this Review, we highlight the latest advances in immunotherapy and discuss the role that it will have in the future of cancer treatment, including settings for which testing combination strategies and 'armoured' CAR T cells are recommended.
DOI：
10.1038/nrclinonc.2016.25
发表时间：
2016-05
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Khalil DN;Smith EL;Brentjens RJ;Wolchok JD
通讯作者：
Wolchok JD